Drug Development Opportunities in China: Regulation, key players and initiatives for domestic and international markets

Drug developments in the US and EU are becoming increasingly expensive and time consuming, with new products typically requiring investment of over 4 years and $1billion from concept to commercialization. As a result, China has emerged as an increasingly attractive option for companies aiming to reduce such prohibitive investments in time and finance. Human clinical studies have historically dominated outsourced R&D activities in China, with the country’s relative lack of capital and expertise being insufficient to facilitate technologically intensive discovery and pre-clinical work. However, an influx of western-trained scientists and increasing access to global capital markets are rapidly extending the development opportunities available to China’s expanding base of pharma and biotech companies. ’Drug Development Opportunities in China’ is a new report published by Business Insights that provides a comprehensive review of China’s drug development industry, both in terms of expanding domestic markets and the country’s role as a third-party provider of outsourced global drug developments. This report will examine the methods of expansion adopted by China’s pharma companies, biotech developers and CRO’s to increase the scale of their drug development operations, in addition to identifying their therapeutic interests and development lifecycle focus. It will also provide forecasts for drug development trends in China over the next five years. Identify the factors attracting global drug developers to China, assess future growth opportunities within the domestic pharma and biotech markets and deploy outsourced R&D more effectively with this new report...